Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

Lipid Nanoparticle-Mediated Base Editor Delivery: Restoring Photoreceptor Function for a Model of Leber Congenital Amaurosis

EF 2024-25

Résumé
Millions worldwide are affected by inherited retinal dystrophies (IRDs), a family of genetic diseases that cause the light-sensing cells of the retina to deteriorate over time, leading to vision loss. GUCY2D is a gene mutated in patients with Leber congenital amaurosis (LCA), a severe type of IRD that affects children. It encodes guanylate cyclase (GC), an enzyme responsible for restoring photoreceptor equilibrium following light stimuli; dysfunctional proteins cause photoreceptor death and the subsequent loss of vision. Since many forms of LCA are caused by a single nucleotide mutation of the impacted gene, it can benefit from novel base editing applications, such as the adenine base editor (ABE). ABEs can be targeted to a desired location in the genome and precisely convert a single T base pair to C. However, since nucleic acids are fragile, they need a delivery method that allows the editor to reach the nucleus. Lipid nanoparticle (LNP) delivery is an ideal method as it is less likely to create undesired immune responses like other alternatives (e.g. adeno-associated viruses). This project will aim to optimize in vitro editing efficiency through EGFP signal, where successful editing of a nonsense mutation in GC will restore EGFP fluorescence. To serve as a proof-of-concept for LCA treatment in humans, mice models expressing the nonsense mutation will be used to evaluate in vivo LNP delivery of the editor and the restoration levels of visual activity. Currently, there is limited research on LNP-mediated delivery of base editors directly to photoreceptor cells. By modelling the disease in a simplified system, this project can inform treatment development for LCA and other hereditary ocular diseases.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530006
Name
Ding Jia Yi
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Lipid Nanoparticle-Mediated Base Editor Delivery: Restoring Photoreceptor Function for a Model of Leber Congenital Amaurosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adenine Base Editor; Gene Editing; Guanylate Cyclase; Inherited Retinal Dystrophy; Leber Congenital Amaurosis; Lipid Nanoparticle; Reporter Model
Abstract
Millions worldwide are affected by inherited retinal dystrophies (IRDs), a family of genetic diseases that cause the light-sensing cells of the retina to deteriorate over time, leading to vision loss. GUCY2D is a gene mutated in patients with Leber congenital amaurosis (LCA), a severe type of IRD that affects children. It encodes guanylate cyclase (GC), an enzyme responsible for restoring photoreceptor equilibrium following light stimuli; dysfunctional proteins cause photoreceptor death and the subsequent loss of vision. Since many forms of LCA are caused by a single nucleotide mutation of the impacted gene, it can benefit from novel base editing applications, such as the adenine base editor (ABE). ABEs can be targeted to a desired location in the genome and precisely convert a single T base pair to C. However, since nucleic acids are fragile, they need a delivery method that allows the editor to reach the nucleus. Lipid nanoparticle (LNP) delivery is an ideal method as it is less likely to create undesired immune responses like other alternatives (e.g. adeno-associated viruses). This project will aim to optimize in vitro editing efficiency through EGFP signal, where successful editing of a nonsense mutation in GC will restore EGFP fluorescence. To serve as a proof-of-concept for LCA treatment in humans, mice models expressing the nonsense mutation will be used to evaluate in vivo LNP delivery of the editor and the restoration levels of visual activity. Currently, there is limited research on LNP-mediated delivery of base editors directly to photoreceptor cells. By modelling the disease in a simplified system, this project can inform treatment development for LCA and other hereditary ocular diseases.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ding, Jia Yi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~